Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biohaven Ltd. Common Shares (NY:BHVN)

16.05 +0.29 (+1.84%)
Streaming Delayed Price Updated: 10:00 AM EDT, Jul 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biohaven Ltd. Common Shares

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
News headline image
The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight ↗
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in,... 
Via Benzinga
Where Biohaven Pharma Hldgs Stands With Analysts ↗
Within the last quarter, Biohaven Pharma Hldgs (NYSE:BHVN) has observed the ... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 29) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
News headline image
Stocks That Hit 52-Week Highs On Thursday ↗
Thursday's morning session saw 167 companies set new 52-week highs. Points of Interest: ASML Holding (NASDAQ:ASML) was the largest company by market cap to set a new... 
Via Benzinga
Analyst Ratings For Biohaven Pharma Hldgs ↗
Analysts have provided the following ratings for Biohaven Pharma Hldgs (NYSE: 
Via Benzinga
Analyst Ratings For Biohaven Pharma Hldgs ↗
Analysts have provided the following ratings for Biohaven Pharma Hldgs (NYSE: 
Via Benzinga
Analyst Ratings For Biohaven Pharma Hldgs ↗
Within the last quarter, Biohaven Pharma Hldgs (NYSE:BHVN) ... 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, AbSci IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) Biohaven Pharmaceutical... 
Via Benzinga
News headline image
Will This Biopharma Company Continue to Crush It? ↗
Migraine sufferers certainly hope so. 
Via The Motley Fool
News headline image
10 Biggest Price Target Changes For Monday ↗
RBC Capital boosted Chipotle Mexican Grill, Inc. (NYSE:C... 
Via Benzinga
News headline image
The Daily Biotech Pulse: J&J, Novartis Report Solid Results, Chembio Soars On COVID Test Order, Lumos Signals Clinical Trial Delay ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 20) Alnylam Pharmaceuticals,... 
Via Benzinga
News headline image
Biohaven Rallies On Preliminary Nurtec Revenue Numbers: What Investors Need To Know ↗
Biohaven Pharmaceutical Ltd. (NYSE:BHVN) released preliminar... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
Gainers Opiant Pharmaceuticals (NASDAQ:OPNT 
Via Benzinga
News headline image
The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 13) Biohaven Pharmaceutical... 
Via Benzinga
News headline image
Here's Why Biohaven Pharmaceutical Is Soaring Today ↗
Preliminary sales figures for the company's new migraine drug were much better than expected. 
Via The Motley Fool
News headline image
The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 8) Aerpio Pharmaceuticals, Inc... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 7) Ambrx Biopharma Inc. (NYSE:... 
Via Benzinga
Topics Product Recall
News headline image
61 Biggest Movers From Yesterday ↗
Gainers Newegg Commerce, Inc. (NASDAQ: NEGG) shares surged 148.4% to close at $67.57 on Wednesday after jumping around 42% on Tuesday. Mannatech, Incorporated (NASDAQ: MTEX)... 
Via Benzinga
News headline image
Jim Cramer Says People Need To Know About Biohaven ↗
Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) announced... 
Via Benzinga
News headline image
Biohaven Stock Hits Record High As Migraine Drug Trounces Quarterly Forecasts ↗
Biohaven crushed Wall Street's expectations for second-quarter sales of migraine drug Nurtec on Tuesday, leading BHVN stock to pop. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Dare Bioscience (NASDAQ:DARE) shares increased by 51.97% to $2.31 during Wednesday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 6) Ambrx Biopharma Inc. (NYSE:... 
Via Benzinga
News headline image
Biohaven Pharmaceutical: Return On Capital Employed Insights ↗
During Q1, Biohaven Pharmaceutical's (NYSE:BHVN) reported sales totaled $43.82 million. Despite a 28.93% in earnings, the company posted a loss of $235.88 million. In Q4, Biohaven... 
Via Benzinga
News headline image
Eli Lilly To Test Injectable Migraine Med Against Biohaven's Oral Nurtec In Head-To-Head Study ↗
Eli Lilly And Co (NYSE: LLY) will conduct a head-to-head study comparing once-monthly injectable Emgality (galcanezumab-gnlm) with Biohaven Pharmaceutical... 
Via Benzinga
News headline image
Biotechs Ready To Roar ↗
The biggest event last week was the FDA decision to approve Biogen's drug aducanumab, a treatment for Alzheimer's disease. The decision will reverberate across the industry and the healthcare sector... 
Via Talk Markets
News headline image
Biotech Movers During ASCO Week ↗
The biotech sector performed well in a good ASCO week. And many biotech stocks were movers this week as a bullish sentiment took hold sparked by the Biogen Aduhelm approval. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 10) Alexion Pharmaceuticals,... 
Via Benzinga
News headline image
Photo of Biohaven Pharmaceuticals Ringing the Opening Bell Available on Business Wire's Website and the Associated Press Photo Network
From Biohaven Pharmaceuticals
Via Business Wire
News headline image
Biohaven Pharmaceutical Insights: Return On Capital Employed ↗
In Q1, Biohaven Pharmaceutical (NYSE:BHVN) posted sales of $43.82 million. Earnings were up 28.93%, but Biohaven Pharmaceutical still reported an overall loss of $235.88 million.... 
Via Benzinga
News headline image
Analyst Ratings for Biohaven Pharma Hldgs ↗
Analysts have provided the following ratings for Biohaven Pharma Hldgs (NYSE:BHVN) within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 2... 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.